Overview
| Name | NeuralPLexer3 · aliases: NeuralPLexer3, NP3 |
|---|---|
| Full name | The name is a product name plus version; the paper gives no expanded form |
| Ambiguous names (not auto-linked) | NeuralPLexer |
| Family | Not a family entry. Earlier NeuralPLexer 1 and 2 fall outside this record, which covers the third generation only |
| Organization | Iambic Therapeutics |
| Organization type | AI-native biotech |
| Country | United States |
| Model class | Co-folding (flow matching) |
| Domain | Structure & co-folding |
| First release | † partly verified · product update Basis: Developer's NP3 Beta preview post Note: The site recorded the arXiv v1 date, 2024-12-14, as first release source |
| Other milestones | |
| Latest update | † partly verified · journal Basis: Main-track entry in the conference proceedings Entered a machine-learning conference's main-track proceedings in December 2025; no weights or main code release was found. Note: The meeting date is month-level; the event is recorded as a proceedings publication source The most recent sourced event, not a claim that nothing changed since. |
| Status | Active · A proceedings event within 12 months, but no code or weights release |
| Openness | Code: Closed · BSD-3-Clause Weights: Closed Weights and main code are not released; only the NPBench evaluation set is open under BSD-3 |
| Benchmarks reported | 3 counted (self 1, modified protocol 1, retrospective 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † first_release, release_milestones.journal_online, latest_update, training_data.c_own_wetlab_for_training, benchmarks_reported |
| As of | 2026-11-16 |
What it does
Generates protein-ligand, protein-protein and peptide complex structures with flow matching, with the paper stressing stereochemistry and physical validity. It is one of two core models on the developer's platform, the other being the property-prediction model Enchant; it differs from AlphaFold3 in its flow architecture and its emphasis on physical validity, and outside users reach it only through partnerships.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 3 of 3 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 05 PoseBusters | Developer report, official protocol | — | Self-reported | V2 set, with validity checks included · evidence |
| 25 RNA-Puzzles | Developer report, modified protocol | — | Self-reported | CASP15 RNA 8-target subset; AF3 baseline copied from its paper, not rerun · evidence |
| 01 CASP | Retrospective dataset use | — | Third-party | Matrix marks a self-report, but page evidence is only CASP15 RNA, duplicated from the RNA-Puzzles column †partly verified · evidence |
Other evaluations (outside the 44)
- Developer's own evaluation set (Own task set) Self-reported: A self-built set of 1,143 targets covering protein-protein interfaces, peptides and conformational change
- Comparison with docking software (Comparison against baselines only) Self-reported: The paper places its results alongside two classical docking programs and one diffusion model
Developers report: a higher share of poses meeting both RMSD under 2 Å and physical validity than AlphaFold3 on the V2 pose set, near-perfect stereochemistry and second-scale inference.
Independent evidence: No independent evidence found. Weights and main code are not public and no third-party rerun of the model was found
Training data
Group in Figure 7: Public data only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | A protein structure archive (before 2020-09-01), about 270,000 distilled entries from a public protein set, and about 12.7 million quantum-chemistry conformers source |
| b. Private or licensed data | No | The paper does not mention the developer's private data source |
| c. Own wet-lab data used for training | Not disclosed | |
| d. Wet lab used only for validation | No |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: The developer is an AI-native oncology drug company founded in 2019 in California by two chemistry professors from a US institute of technology and a UK university, growing out of a quantum-chemistry software company; its platform spans structure prediction, property prediction and synthesis planning. It listed on a US exchange in September 2026.
- Funding: A $100M Series B plus a $50M extension in June 2024; a September 2026 listing of 9.4 million shares at $16 raised about $150M, with the prospectus allocating roughly $20M to training new versions of its two core models.
- Products and partnerships: Its pipeline includes a Phase 1 oral HER2 inhibitor and two preclinical programmes; partners include a Japanese pharmaceutical company (reported milestones up to $1.7B), a US oncology company ($25M for custom training) and another large pharmaceutical company.
- Related models: AlphaFold 3, Boltz-2, Enchant v1/v2
Reading notes
- The comparison with AlphaFold3 rests on numbers the paper recomputed itself; other papers report widely differing figures, so any citation needs its source.
- Without the physical-validity requirement the two are close, so the advantage sits in validity alone.
- With no public weights nothing can be rechecked externally; only the open evaluation set is reproducible.
- The RNA comparison uses eight targets with baselines quoted from another paper, so it carries little weight.
Caveats
- Weights and main code are unreleased; outside use runs through partnerships.
- First release is taken from the developer preview post, with the paper v1 later; both are recorded.
- The proceedings event is pinned only to the month of the meeting.
- The CASP pairing reuses the RNA evidence and remains to be rechecked.
- Own wet-lab training data is not disclosed, which is not the same as none.
Sources
- Preprint 2024 (preprint)
- Preprint full text v2 (preprint)
- Conference proceedings entry 2025 (paper)
- Developer Beta preview post (company blog)
Corrections
1 correction
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| first_release | 2024-12-14(arXiv v1) | 2024-11-01 (developer beta preview post); arXiv v1 kept as paper_v1 | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.